bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

First computational design of Covid-19 coronavirus
vaccine using lambda superstrings

Luis Mart√≠nez1,2, Iker Malaina1,9, David Salcines3, H√©ctor Ter√°n3, Santos Alegre4,5, I.M. De la
Fuente6,1, Elena Gonzalez Lopez7, Gonzalo Ocejo Vinyals7, Carmen √Ålvarez8

1. Department of Mathematics, Faculty of Science and Technology, University of the
Basque Country, UPV/EHU, Leioa, Spain, 48940.
2. BCAM, Basque Center for Applied Mathematics, Bilbao, Spain, 48009.
3. Instituto de Investigaci√≥n Marqu√©s de Valdecilla, Santander, Spain, 39011
4. Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of
Science and Technology, University of the Basque Country, UPV/EHU, Leioa, Spain,
48940.
5. Mar√≠a Goyri Building. Animal Biotechnology Center. University of the Basque Country,
UPV/EHU, Leioa, Spain, 48940.
6. Department of Nutrition, CEBAS-CSIC Institute, Espinardo University Campus, Murcia,
Spain, 30100.
7. Servicio de Inmunolog√≠a, Hospital Universitario Marqu√©s de Valdecilla, Santander,
Spain, 39008.
8. Facultad de Educaci√≥n, Universidad Internacional de La Rioja, Logro√±o, La Rioja, Spain,
26006
9. BioCruces Health Research Institute, Cruces University Hospital, Barakaldo, Spain,
48903.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Corresponding Author:
Luis Mart√≠nez.
University of the Basque Country UPV/EHU,
Faculty of Science and Technology, Department of Mathematics,
Leioa, Spain, 48940.
TEL: +34 946 01 2651
Email: luis.martinez@ehu.eus

Abstract
In this work we have developed, by employing lambda superstrings, a map of candidate
vaccines against SARS-CoV-2 with lengths between 9 and 200, based on estimations of the
immunogenicity of the epitopes and the binding affinity of epitopes to MHC class I molecules
using tools from the IEDB Analysis Resource, as well as the overall predictions obtained using
the VaxiJen tool. We have synthesized one of the peptides, specifically the one of length 22,
and we have carried out an immunogenicity assay and a cytokine assay, which has given
positive results in both cases.

1. Introduction
The Covid-19 coronavirus epidemic represents the greatest global threat to human health at
the current juncture, with more than 60 million persons infected and more than 1.4 million
persons died worldwide in the 11 months since the disease was detected. In order to stop this
epidemic, different types of vaccines are being developed in an accelerated manner, mostly, if
not all, based on well-known classical methods. Despite the fact that several effective vaccines
are available, their effectiveness has been demonstrated only in clinical trials, and it remains to

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

be checked if the obtained percentages of protection will be maintained in the whole
population and, above all, for how long will the obtained immunity last. This makes imperative
to continue searching for new candidate vaccines against SARS-CoV-2.
We present here a candidate for a vaccine for the SARS-CoV-2 virus designed entirely from
computational methods and advanced tools of artificial intelligence. This new method of
intelligent vaccine design is based on developing, first, one or several candidates that allow to
cover the maximum number of possible mutations, doing then the molecular sequencing of
the candidates, and performing then the subsequent in vitro and in vivo tests and, finally, the
clinical analysis.
Our method is based in the concept of Œª-superstring, introduced by our research team in [6]. In
that paper, we presented a new criterion for the selection of epitopes in the design of vaccines
which is well suited to consider all the mutations of the pathogen so that there is a balance of
the covering of the candidate vaccine among all the mutated versions of the target protein.
Specifically, we considered a set of target strings, formed by the epitopes that can be selected
for the candidate vaccine, and a set of host strings, constituted by the different variants of the
target protein, in which the known mutations are considered. In that context, given the value
of a parameter Œª, a Œª-superstring is a sequence of aminoacids with the property that the string
covers at least Œª epitopes in each of the host strings.
The concept of Œª-superstring was generalized later by us in [7] to the one of weighted Œªsuperstring by allowing the epitopes to be weighted by their immunogenicities. This
generalization entails an important improvement in the applications to vaccine design, as this
weighting of the immunogenicities gets closer to the biological and medical practice, and
increases the likelihood that the obtained candidate vaccines are effective. In fact, the use of
weighted Œª-superstrings could be useful to fight the high mutability and escape mutations of
viruses like HIV, HCV, or Influenza.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Here, we have used Integer Programming to obtain the best solution for the weighted lambdasuperstring problem, applied to the surface protein of SARS-COV-2, obtaining sequences for
the Spike protein which offer potential protection against all the virus variants considered for
the study (in this case, all the sequences appearing in GISAID ([4]) webside (until March 4,
2020). In consequence, the objective of our proposal is not only to develop an effective
vaccine for the current pandemic, but also to give protection against potential mutations of
the virus, and stop its expansion and possible comeback.
Specifically, in order to select the most promising epitopes for the vaccine, we have first
associated a weight to each potential 9-mer epitope. More precisely, we have estimated the
immunogenicity and HLA-binding affinity of class I potential epitopes, which makes our
candidates appropriate to be used worldwide. As a result of our computations, we present
here a map of optimal candidate vaccines with different lengths, which on one hand optimize
both immunogenicity and HLA-binding affinity, and on the other hand, give a balanced
protection against all the sequenced variants of Covid-19 surface protein so far. We have
selected from this map a peptide of length 22 and we have made in-vivo experimental tests
that have given positive results in both immunogenicity assays and cytokine assays.
Our approach gives optimal solutions and therefore represents an efficient alternate insight to
vaccine design for SARS-CoV-2 virus.
The main objective of this manuscript is that vaccine specialists become aware of this new
method of vaccine design, so that, together, as soon as possible, an efficient vaccine against
Covid-19 can be developed.
2. Materials and Methods
2.1 Extraction of the sequences
The sequences were taken from two sources: GenBank ([3]) and GISAID ([4]).

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

In Genbank the search ‚ÄúSevere acute respiratory s√≠ndrome coronavuirus 2‚Äù AND ‚ÄúHomo
sapiens‚Äù was done in Nucleotide. The results of the search were saved as Coding Sequences in
format FASTA Protein in order to get the information about the corresponding aminoacids.
After that, the generated file was read and the sequences corresponding to ‚Äúsurface‚Äù or to
‚Äúspike‚Äù protein (it is the same protein, but in GenBank it appeared as surface in some cases
and as spike in other cases) were selected.
The search in GISAID was restricted by selecting ‚ÄúHuman‚Äù in the host window and clicking
‚Äúcomplete‚Äù (>29000bp) in order to obtain only complete genomes in human hosts. The
information about the surface protein was extracted from the genomes by using the GeneWise
([5]) tool, by putting in the protein window the sequence of aminoacids corresponding to the
surface glycoprotein (YP_009724390.1) product in the reference genome (NC_045512.2).
Duplicated sequences were removed, keeping just a single copy of each one of them, as well as
the ones containing some of the ambiguous characters ‚ÄúX‚Äù,‚ÄùB‚Äù,‚ÄùZ‚Äù,‚ÄùJ‚Äù,‚ÄùO‚Äù,‚ÄùU‚Äù,‚Äù.‚Äù,‚Äù*‚Äù. An
anomalously short sequence of length 35 was disregarded.
The resulting 22 sequences were taken as host strings, constituting the set ùêª.
2.2 Weighting of the epitopes
The set ùëá of target strings was taken to be the set of 9-tuples of elements of ùê¥ (where ùê¥ is the
set of 20 aminoacids) that are contained in at least one target string.
The way in which the weight ùë§(ùë†) associated to a host string (epitope) ùë† was calculated is as
follows:
1) The estimation ùëñ(ùë†) of the immunogenicity of ùë† was calculated with the ‚ÄúT cell class I
PMHC immunogenicity predictor‚Äù of IEDB.
2) The set ùê¥ùêº(ùë†) of alleles of the HLA-I allele reference set with the ‚ÄúPeptide binding to
MHC class I molecules‚Äù tool of IEDB which pass the threshold was computed, and the

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

number ùëèùêº(ùë†) = ‚àëùëñ‚ààùê¥ùêº(ùë†) ùëì(ùëé) was calculated, where ùëì(ùëé) is the estimated global
frequency of the allele ùëé in ‚ÄúThe Allele Frequency Net Database‚Äù.
Next, the normalized families were computed in the following way:
ùëñùëÅ (ùë†) =

ùëñ(ùë†)‚àíùëöùëñ
,
ùëÄùëñ ‚àíùëöùëñ

ùëèùêºùëÅ (ùë†) =

where ùëöùëñ = ùëöùëñùëõùë†‚ààùëá ùëñ(ùë†) and ùëÄùëñ = ùëöùëéùë•ùë†‚ààùëá ùëñ(ùë†),

ùëèùêº(ùë†)‚àíùëöùëèùêº
,
ùëÄùëèùêº ‚àíùëöùëèùêº

where ùëöùëèùêº = ùëöùëñùëõùë†‚ààùëá ùëèùêº(ùë†) and ùëÄùëèùêº = ùëöùëéùë•ùë†‚ààùëá ùëèùêº(ùë†).

Finally, the weight of the epitope ùë† was taken as
ùë§(ùë†) =

3 ùëñùëÅ (ùë†)+ùëèùêºùëÅ
.
4

2.3 Optimization with CPLEX
CPLEX Optimizer ([2]) was used to solve the integer programming algorithm described in [7] in
order to maximize the value of Œª for a fixed maximum length with the set of host strings
described in Subsection 2.1 and the set of target strings and weights described in Subsection
2.2.
2.4 Ranking the candidates with Vaxijen
The bioinformatic tool Vaxijen ([10]) was used with each one of the candidates obtained with
the optimization done with CPLEX. ‚ÄúVirus‚Äù was selected as target organism. The overall
prediction for the protective antigen was calculated for each sequence and the ones over the
threshold of 0.4 established for the model were selected.
3. Results
Given two sets ùêª and ùëá of strings, called host strings and target strings, respectively, and given
a mapping : ùë§: ùêª ‚Üí ‚Ñù , we say that a string ùë† is a weighted Œª‚Äìsuperstring if, for every ‚Ñé ‚àà ùêª ,
the inequality ‚àëùë°‚ààùëá,ùë°‚â§ùë† ùë§(ùë°) ‚â• ùúÜ holds.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

We have taken as host strings the 22 distinct sequences corresponding to the Surface protein
of SARS-COV-2 appearing in Genbank ([3]) and in the GISAID database ([4]).
We have taken as target strings, that is, as potential epitopes, the 9-mers contained in some of
the 22 host strings.
We have weighted the epitopes having into account the estimation of their immunogenicities
and the estimation of the binding affinity to HLA-I.
We have calculated a weighted Œª‚Äìsuperstring with maximum Œª for a length between 9 and
200. For each one of them we have calculated also the VaxiJen overall prediction. These
optimal weighted Œª‚Äìsuperstring, as well as the corresponding Œª values and VaxiJen predictions
are shown in Table 1. Each Œª‚Äìsuperstring can be divided in a natural way as a union of a small
number of peptides located at different parts of the protein. These peptides are enumerated,
for each Œª‚Äìsuperstring, in the fourth column of the table. When a peptide has some
intersection with a domain of the protein, the domain is annotated next to the peptide. For
the Œª‚Äìsuperstrings of lengths from 176 to 183 the third peptide intersects two domains: NTD
and RBD.
We have chosen one of the candidate vaccines for which the overall prediction in VaxiJen
exceeds 0.4, which is the threshold of the highest accuracy value beyond which the sequence
is considered to be a probable antigen. Specifically, we have taken the peptide of length 22,
STQDLFLPFFSNVTWFHAIHVS , which is contained in the NTD domain and has an overall
prediction of 0.5545 in VaxiJen. We have synthesized the peptide, and we have done some in
vivo experimental proofs to test its immunogenicity and putative efficiency.
First proof of concept regards to immunogenicity of the antigen prepared, SARS-CoV-2NTD peptide of 22 amino acids (here named as COVID-19-NTD). We used a procedure
previously described ([1]) that evaluates the best immunogenic epitopes for preparing
vaccines. The assay consists of measuring the delayed type hypersensitivity (DTH) response of

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

a vaccine vector, such as dendritic cells (DC) loaded with the peptide, in a vaccine formulation
with an adjuvant. Next, we inoculated the vaccine formulation into the left hind footpads of
mice, serving the non-inoculated right hind footpads as basal controls. Forty-eight hours later,
we measured the DTH response as the swelling of the left hind footpads compared to the right
hind footpads. We also included empty DC in these experiments and DC loaded with a control
peptide non-related to SARS-CoV-2 virus. Analysis of DTH responses indicated that DC loaded
with COVID-19-NTD peptide were significantly higher than immune responses elicited by DC
loaded with the control peptide or empty DC (blue bars in Figure 1). Next, we collected the
popliteal lymph nodes and cultured them in vitro with 1 ¬µg/mL of each peptide, COVID-19NTD, control peptide or saline for 72 hours to examine the main immune populations by flow
cytometry. We observed that the highest percentages of immune cells corresponded to CD19+
cells (27,63 %) that usually correspond to B cells, followed by MHC-II+ cells (20, 45%) that
usually labels DC and macrophages, next CD4+ T cells (10,39%) and CD8+ T cells (4,61%). The
control peptide does not produce significant immune responses, we only observed very small
percentages of CD19+ cells (4,61%) and moderate ranges of MHC-II+ cells (11,5%) (DC-peptide
CONT bars in Figure 1). Empty DC did not induce significant percentages of immune cells.
These results indicate a clear induction of immune cells by DC vaccines loaded with COVID19NTD peptide that stimulate immune cells involved in antibody formation, such as B cells, DC
and CD4+ T cells. While not predominant, cytotoxic immune responses caused by CD8+ T cells
are also induced by DC vaccines loaded with COVID-19-NTD peptide. These results are not
surprising since CD4+ and CD8+ T cell epitopes are recovered from patients with mild and
severe COVID-19 that were specific for the spike protein ([8]).
Second proof of concept related with the production of cytokines, either pro-inflammatory
cytokines such as TNF-a, IFN-g, IL-2, KC and IL-12 or anti-inflammatory cytokines as IL-4, IL-6,
MIP-2 or IL-10. Covid-19 cytokine storm in severe patients correlates with very high levels of
TNF-a, IL-6, IL-4 and IL-10, as well as with a clear deficiency in the production of IFN related

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

cytokines (i.e, IFN-a, IFN-g or IL-12) ([9]). Our results in Figure 2 showed that DC loaded with
COVID19-NTD peptide produced mainly the pro-inflammatory cytokines, IL-12, IL-17A and IL-2.
However, this DC-COVID-19-NTD vaccine platform does not induce anti-inflammatory
cytokines participating in COVID-19 cytokine storm such as IL-6, IL-10 or TNF-a (bars labelled
with DC-COVID19-NTD in Figure 2). Interesting, DC-COVID-19-NTD vaccines induced high levels
of IFN-g (blue bars in Figure 2) and barely no levels of MIP-2, an inflammatory cytokine that
recruits inflammatory macrophages (grey bars in Figure 2). The lack of significant levels of IL-4
(orange bars in Figure 2), while high levels of IL-2 (red bars) suggests induction of a Th1-Th17
type immune responses, but with no exacerbation of the pro-inflammatory cytokines as TFN-a
or MIP-2. In summary, high levels of IFN-g and especially IL-12 cytokines that involved on
vaccine efficiency and anti-viral responses, prompted us to suggest that COVID19-NTD peptide
might function as an immunogenic epitope. COVID19-NTD peptide might be a good candidate
to prepare efficient vaccine platforms that induce not only antibody production but strong
anti-viral T cell responses.
4. Discussion
The selected candidate vaccine elicited a strong immune response in mice with Th1-Th17 proinflammatory features with strong stimulation of cells involved in antibody production but also
with production of anti-viral cytokines. This shows the adequacy of using Œª-superstrings to find
an efficient vaccine against SARS-CoV-2.
The exploration of the candidate vaccines in the table of the previous section could lead to the
obtention of a vaccine that covers a high percentage of the population. Candidate vaccines in
the table for which the overall prediction in VaxiJen is greater than 0.4, which is the threshold
for the highest accuracy, are specially interesting, but it could be useful to consider also values
close to 0.4, say for instance over 0.37.
5

References

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

1. Calder√≥n-Gonz√°lez R, Tobes R, Pareja E, Frande-Cabanes E, Alaez-√Ålvarez L, Petrovsky N
and √Ålvarez-Dom√≠nguez C. (2015). Identification and characterisation of T-cell epitopes for
incorporation into dendritic cell-delivered Listeria vaccines. J Immunol Methods. 424: 111-119.
doi: 10.1016/j.jim.2015.05.009.
2. https://www.ibm.com/analytics/cplex-optimizer
3. https://www.ncbi.nlm.nih.gov/genbank/
4. https://platform.gisaid.org/epi3/frontend#3898c7
5. https://www.ebi.ac.uk/Tools/psa/genewise/
6. Mart√≠nez L, Milanic M, Legarreta L, Medvedev P, Malaina I, De la Fuente IM. A combinatorial
approach to the design of vaccines. J Math Biol. 2015; 70:1327-1358.
7. Mart√≠nez L, Milanic M, Malaina I, Alvarez C, P√©rez MB, De la Fuente IM. Weighted lambda
superstrings applied to vaccine design. Plos One,
https://doi.org/10.1371/journal.pone.0211714 February 8, 2019.
8. Peng Y, Mentzer AK, Liu G et al. (2020) Broad and strong memory CD4+ and CD8+ T cells
induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature
Immunol 21(11):1336-1345. doi: 10.1038/s41590-020-0782-6.
9. Zhang Y, Chen Y, Meng Z. (2020). Immunomodulation for severe COVID-19 pneumonia:
the State of the Art. Front Immunol 11:577442. doi: 10.3389/fimmu.2020.577442
10. http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Table 1: optimal weighted Œª‚Äìsuperstring, Œª values and VaxiJen overall prediction for lengths
between 9 and 276.

Length

Lambda

Prediction

Sequence

9

0.75

-0.2311

1:IRGWIFGTT(NTD)

10

1.49

-0.8187

1:SNIIRGWIFG(NTD)

11

2.24

-0.3450

1:NIIRGWIFGTT(NTD)

12

2.99

-0.3537

1:SNIIRGWIFGTT(NTD)

13

3.7

-0.5324

1:KSNIIRGWIFGTT(NTD)

14

4.37

-0.5608

1:KSNIIRGWIFGTTL(NTD)

15

4.96

-0.3688

1:EKSNIIRGWIFGTTL(NTD)

16

5.53

-0.2956

1:EKSNIIRGWIFGTTLD(NTD)

17

6.05

-0.3730

1:EKSNIIRGWIFGTTLDS(NTD)

18

6.48

-0.2974

1:TEKSNIIRGWIFGTTLDS(NTD)

19

6.9

0.0025

1:TEKSNIIRGWIFGTTLDSK(NTD)

20

7.23

0.0044

1:STEKSNIIRGWIFGTTLDSK(NTD)

21

7.54

0.0359

1:ASTEKSNIIRGWIFGTTLDSK(NTD)

22

8.03

0.5545

1:STQDLFLPFFSNVTWFHAIHVS(NTD)

23

8.54

0.3591

1:STQDLFLPFFSNVTWFHAIHVSG(NTD)

24

9.02

0.4796

1:STQDLFLPFFSNVTWFHAIHVSGT(NTD)

25

9.47

0.2571

1:DGKAHFPREGVFVSNGTHWFVTQRN(CD)

26

10.02

0.3869

1:FVSNGTHWFVTQRNFYEPQIITTDNT(CD)

27

10.54

0.3742

1:FVSNGTHWFVTQRNFYEPQIITTDNTF(CD)

28

11.06

0.3592

1:FVSNGTHWFVTQRNFYEPQIITTDNTFV(CD)

29

11.6

0.3892

1:FVSNGTHWFVTQRNFYEPQIITTDNTFVS
(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

30

12.07

0.3131

1:FVSNGTHWFVTQRNFYEPQIITTDNTFVSG
(CD)

31

12.56

0.2632

1:QPTESIVRFPNITNLCPFGEVFNATRFASVY
(RBD)

32

13.05

0.3711

1:VQPTESIVRFPNITNLCPFGEVFNATRFASVY
(RBD)

33

13.52

0.3698

1:VQPTESIVRFPNITNLCPFGEVFNATRFASVY
A(RBD)

34

14

0.3097

1:KAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DN(CD)

35

14.59

0.3260

1:KAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNT
(CD)

36

15.17

0.3278

1:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNT
(CD)

37

15.68

0.3198

1:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTF
(CD)

38

16.21

0.3107

1:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFV
(CD)

39

16.74

0.3341

1:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVS
(CD)

40

17.24

0.3078

1:DGKAHFPREGVFVSNGTHWFVTQRNFYEPQII
TTDNTFVS(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

41

17.72

0.2556

1:DGKAHFPREGVFVSNGTHWFVTQRNFYEPQII
TTDNTFVSG(CD)

42

18.18

0.2660

1:DGKAHFPREGVFVSNGTHWFVTQRNFYEPQII
TTDNTFVSGN(CD)

43

18.62

0.2511

1:DGKAHFPREGVFVSNGTHWFVTQRNFYEPQII
TTDNTFVSGNC(CD)

44

19.01

0.2414

1:HDGKAHFPREGVFVSNGTHWFVTQRNFYEPQI
ITTDNTFVSGNC(CD)

45

19.4

0.2132

1:CHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQ
IITTDNTFVSGNC(CD)

46

19.76

0.1944

1:ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP
QIITTDNTFVSGNC(CD)

47

20.16

0.2598

1:TAPAICHDGKAHFPREGVFVSNGTHWFVTQRN
FYEPQIITTDNTFVS(CD)

48

20.69

0.2454

1:KNFTTAPAICHDGKAHFPREGVFVSNGTHWFV
TQRNFYEPQIITTDNT(CD)

49

21.24

0.2717

1:EKNFTTAPAICHDGKAHFPREGVFVSNGTHWF
VTQRNFYEPQIITTDNT(CD)

50

21.76

0.2667

1:EKNFTTAPAICHDGKAHFPREGVFVSNGTHWF
VTQRNFYEPQIITTDNTF(CD)

51

22.28

0.2612

1:EKNFTTAPAICHDGKAHFPREGVFVSNGTHWF
VTQRNFYEPQIITTDNTFV(CD)

52

22.82

0.2796

1:EKNFTTAPAICHDGKAHFPREGVFVSNGTHWF
VTQRNFYEPQIITTDNTFVS(CD)

53

23.32

0.3250

1:QEKNFTTAPAICHDGKAHFPREGVFVSNGTHW
FVTQRNFYEPQIITTDNTFVS(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

54

23.79

0.2857

1:QEKNFTTAPAICHDGKAHFPREGVFVSNGTHW
FVTQRNFYEPQIITTDNTFVSG(CD)

55

24.28

0.2378

1:FFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDG
VYFASTEKSNIIRGWIFGTTLDS(NTD)

56

24.77

0.3126

1:LPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFN
DGVYFASTEKSNIIRGWIFGTTLD(NTD)

57

25.28

0.2794

1:LPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFN
DGVYFASTEKSNIIRGWIFGTTLDS(NTD)

58

25.75

0.2722

1:FLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPF
NDGVYFASTEKSNIIRGWIFGTTLDS(NTD)

59

26.21

0.2321

1:LFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLP
FNDGVYFASTEKSNIIRGWIFGTTLDS(NTD)

60

26.78

0.2699

1:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

61

27.31

0.2767

1:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

62

27.84

0.2893

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)

63

28.35

0.2598

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

64

28.77

0.3308

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)

65

29.06

0.3140

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKT

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

(NTD)
66

29.29

0.3344

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ
(NTD)

67

29.79

0.4214

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
T(CD)

68

30.3

0.4153

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TF(CD)

69

30.83

0.4090

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFV(CD)

70

31.36

0.4203

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVS(CD)

71

31.84

0.3893

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVSG(CD)

72

32.3

0.3930

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVSGN(CD)

73

32.75

0.3826

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVSGN(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

74

33.19

0.3730

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVSGNC(CD)

75

33.56

0.3458

1:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVSGNC(CD)

76

33.92

0.3364

1:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVSGNCD(CD)

77

34.24

0.3248

1:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVSGNCDV(CD)

78

34.51

0.3250

1:SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAIC
HDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVSGNCDV(CD)

79

34.79

0.3380

1:MSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAI
CHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQII
TTDNTFVSGNCDV(CD)

80

35.14

0.3279

1:HLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAP
AICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQ
IITTDNTFVSGNCD(CD)

81

35.46

0.3171

1:HLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAP
AICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQ
IITTDNTFVSGNCDV(CD)

82

35.8

0.2706

1:DGKAHFPREGVFVSNGTHWFVTQRNFYEPQII
TTDNTFVSG(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGW
IFGTTLDSK(NTD)
83

36.19

0.2654

1:HDGKAHFPREGVFVSNGTHWFVTQRNFYEPQI
ITTDNTFVSG(CD)
2:TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGW
IFGTTLDSK(NTD)

84

36.58

0.2505

1:CHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQ
IITTDNTFVSG(CD)
2:TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGW
IFGTTLDSK(NTD)

85

36.94

0.2402

1:ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP
QIITTDNTFVSG(CD)
2:TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGW
IFGTTLDSK(NTD)

86

37.34

0.2613

1:EKSNIIRGWIFGTTLDS(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSG(CD)

87

37.84

0.3043

1:FVSNGTHWFVTQRNFYEPQIITTDNT(CD)
2:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLDS(NTD)

88

38.3

0.1983

1:TAPAICHDGKAHFPREGVFVSNGTHWFVTQRN
FYEPQIITTDNTFVSG(CD)
2:TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGW
IFGTTLDS(NTD)

89

38.87

0.2950

1:KAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTF(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:FSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGV
YFASTEKSNIIRGWIFGTTLD(NTD)
90

39.45

0.2964

1:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTF(CD)
2:FSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGV
YFASTEKSNIIRGWIFGTTLD(NTD)

91

39.96

0.2760

1:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTF(CD)
2:FSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGV
YFASTEKSNIIRGWIFGTTLDS(NTD)

92

40.47

0.2729

1:FFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDG
VYFASTEKSNIIRGWIFGTTLD(NTD)
2:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFV(CD)

93

41.01

0.2830

1:FFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDG
VYFASTEKSNIIRGWIFGTTLD(NTD)
2:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVS(CD)

94

41.49

0.3018

1:PFFSNVTWFHAIHVSGTNGTKRFDNPVLPFND
GVYFASTEKSNIIRGWIFGTTLD(NTD)
2:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVS(CD)

95

42.01

0.3067

1:LPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFN
DGVYFASTEKSNIIRGWIFGTTLD(NTD)
2:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVS(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

96

42.48

0.3023

1:FLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPF
NDGVYFASTEKSNIIRGWIFGTTLD(NTD)
2:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVS(CD)

97

42.99

0.2931

1:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNT(CD)
2:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLDS(NTD)

98

43.51

0.2898

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)
2:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNT(CD)

99

44.02

0.2869

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)
2:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTF(CD)

100

44.58

0.3080

1:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

101

45.1

0.2895

1:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

102

45.6

0.2798

1:DGKAHFPREGVFVSNGTHWFVTQRNFYEPQII
TTDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

103

46.02

0.2766

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)
2:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVSGN(CD)

104

46.46

0.2710

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)
2:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVSGNC(CD)

105

46.82

0.2649

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)
2:GKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVSGNCD(CD)

106

47.25

0.2723

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTT(NTD)
2:APAICHDGKAHFPREGVFVSNGTHWFVTQRNF
YEPQIITTDNTFVS(CD)

107

47.73

0.2534

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTT(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:APAICHDGKAHFPREGVFVSNGTHWFVTQRNF
YEPQIITTDNTFVSG(CD)
108

48.19

0.2570

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTT(NTD)
2:APAICHDGKAHFPREGVFVSNGTHWFVTQRNF
YEPQIITTDNTFVSGN(CD)

109

48.63

0.2518

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTT(NTD)
2:APAICHDGKAHFPREGVFVSNGTHWFVTQRNF
YEPQIITTDNTFVSGNC(CD)

110

49.06

0.2737

1:EKNFTTAPAICHDGKAHFPREGVFVSNGTHWF
VTQRNFYEPQIITTDNT(CD)
2:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLDS(NTD)

111

49.56

0.2949

1:NFTTAPAICHDGKAHFPREGVFVSNGTHWFVT
QRNFYEPQIITTDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

112

50.11

0.2766

1:KNFTTAPAICHDGKAHFPREGVFVSNGTHWFV
TQRNFYEPQIITTDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

113

50.66

0.2874

1:EKNFTTAPAICHDGKAHFPREGVFVSNGTHWF
VTQRNFYEPQIITTDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

114

51.17

0.2713

1:EKNFTTAPAICHDGKAHFPREGVFVSNGTHWF
VTQRNFYEPQIITTDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

115

51.67

0.2918

1:QEKNFTTAPAICHDGKAHFPREGVFVSNGTHW
FVTQRNFYEPQIITTDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

116

52.09

0.3300

1:QEKNFTTAPAICHDGKAHFPREGVFVSNGTHW
FVTQRNFYEPQIITTDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)

117

52.49

0.3297

1:AQEKNFTTAPAICHDGKAHFPREGVFVSNGTH
WFVTQRNFYEPQIITTDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)

118

52.88

0.3222

1:PAQEKNFTTAPAICHDGKAHFPREGVFVSNGT
HWFVTQRNFYEPQIITTDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)

119

53.21

0.3307

1:VPAQEKNFTTAPAICHDGKAHFPREGVFVSNG
THWFVTQRNFYEPQIITTDNTFVS(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)
120

53.54

0.3181

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ
(NTD)
2:EKNFTTAPAICHDGKAHFPREGVFVSNGTHWF
VTQRNFYEPQIITTDNTFVSGN(CD)

121

54.07

0.3557

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TF(CD)
2:FSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGV
YFASTEKSNIIRGWIFGTTLD(NTD)

122

54.58

0.3401

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TF(CD)
2:FSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGV
YFASTEKSNIIRGWIFGTTLDS(NTD)

123

55.1

0.3414

1:FFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDG
VYFASTEKSNIIRGWIFGTTLDS(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VS(CD)

124

55.58

0.3551

1:PFFSNVTWFHAIHVSGTNGTKRFDNPVLPFND
GVYFASTEKSNIIRGWIFGTTLDS(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VS(CD)
125

56.1

0.3585

1:LPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFN
DGVYFASTEKSNIIRGWIFGTTLDS(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VS(CD)

126

56.57

0.3547

1:FLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPF
NDGVYFASTEKSNIIRGWIFGTTLDS(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VS(CD)

127

57.09

0.3649

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
T(CD)
2:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

128

57.61

0.3500

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
T(CD)
2:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLDS(NTD)

129

58.12

0.3561

1:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VS(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)
130

58.66

0.3508

1:SAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK
AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNT
FVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

131

59.2

0.3600

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

132

59.72

0.3455

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

133

60.17

0.3403

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

134

60.59

0.3729

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVS(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)
135

60.96

0.3580

1:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)

136

61.3

0.3724

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ
S(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSG(CD)

137

61.76

0.3744

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ
S(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGN(CD)

138

62.2

0.3695

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ
S(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNC(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

139

62.56

0.3642

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ
S(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNCD(CD)

140

62.88

0.3578

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ
S(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNCDV(CD)

141

63.01

0.3140

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)
2:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVSGNCDV(CD)

142

63.3

0.3307

1:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVSGNCDV(CD)
2:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKT
(NTD)

143

63.65

0.3453

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ
S(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVSGNCD(CD)
144

63.97

0.3392

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ
S(NTD)
2:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVSGNCDV(CD)

145

64.32

0.3381

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)
2:GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTT
APAICHDGKAHFPREGVFVSNGTHWFVTQRNFYE
PQIITTDNTFVSGNC(CD)

146

64.69

0.3111

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)
2:KVEAEVQIDRLITGRLQS(CH)
3:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
(CD)

147

65.21

0.3100

1:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)
2:KVEAEVQIDRLITGRLQS(CH)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

3:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VS(CD)
148

65.75

0.3150

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)
2:KVEAEVQIDRLITGRLQS(CH)
3:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VS(CD)

149

66.22

0.3012

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)
2:KVEAEVQIDRLITGRLQS(CH)
3:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSG(CD)

150

66.68

0.3034

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)
2:KVEAEVQIDRLITGRLQS(CH)
3:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGN(CD)

151

67.12

0.2994

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:KVEAEVQIDRLITGRLQS(CH)
3:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNC(CD)
152

67.48

0.2951

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLD
(NTD)
2:KVEAEVQIDRLITGRLQS(CH)
3:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNCD(CD)

153

67.91

0.3466

1:SAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK
AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNT
FVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYST
3:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

154

68.45

0.3545

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYST
3:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

155

68.96

0.3422

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYST

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

3:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLDS(NTD)
156

69.41

0.3378

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYST
3:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLDS(NTD)

157

69.83

0.3655

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYST
3:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)

158

70.2

0.3530

1:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYST
3:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)

159

70.64

0.3299

1:QPTESIVRFPNITNLCPFGEVFNATRFAS
(RBD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VS(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

3:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
160

71.17

0.3433

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
V(CD)
3:QPTESIVRFPNITNLCPFGEVFNATRFASV
(RBD)

161

71.69

0.3303

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
V(CD)
3:QPTESIVRFPNITNLCPFGEVFNATRFASVY
(RBD)

162

72.16

0.3303

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
V(CD)
3:QPTESIVRFPNITNLCPFGEVFNATRFASVYA
(RBD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

163

72.58

0.3533

1:RVQPTESIVRFPNITNLCPFGEVFNATRFASV
YA(RBD)
2:PHGVVFLHVTYVPAQEKNFTTAPAICHDGKAH
FPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFV
S(CD)
3:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

164

72.99

0.3797

1:RVQPTESIVRFPNITNLCPFGEVFNATRFASV
YA(RBD)
2:PHGVVFLHVTYVPAQEKNFTTAPAICHDGKAH
FPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFV
S(CD)
3:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)

165

73.37

0.3798

1:NFRVQPTESIVRFPNITNLCPFGEVFNATRFA
SVYA(RBD)
2:PHGVVFLHVTYVPAQEKNFTTAPAICHDGKAH
FPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFV
S(CD)
3:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

166

73.91

0.3993

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVS(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
3:NFRVQPTESIVRFPNITNLCPFGEVFNATRFA
SV(RBD)
167

74.43

0.3863

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
3:NFRVQPTESIVRFPNITNLCPFGEVFNATRFA
SVY(RBD)

168

74.9

0.3860

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
3:NFRVQPTESIVRFPNITNLCPFGEVFNATRFA
SVYA(RBD)

169

75.35

0.3817

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

3:NFRVQPTESIVRFPNITNLCPFGEVFNATRFA
SVYA(RBD)
170

75.75

0.3711

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
3:NFRVQPTESIVRFPNITNLCPFGEVFNATRFA
SVYAW(RBD)

171

76.12

0.3595

1:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
3:NFRVQPTESIVRFPNITNLCPFGEVFNATRFA
SVYAW(RBD)

172

76.57

0.3616

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSG(CD)
3:IYQTSNFRVQPTESIVRFPNITNLCPFGEVFN
ATRFASVY(RBD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

173

77.04

0.3614

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSG(CD)
3:IYQTSNFRVQPTESIVRFPNITNLCPFGEVFN
ATRFASVYA(RBD)

174

77.44

0.3512

1:STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDN
PVLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSG(CD)
3:IYQTSNFRVQPTESIVRFPNITNLCPFGEVFN
ATRFASVYAW(RBD)

175

77.85

0.4263

1:QEKNFTTAPAICHDGKAHFPREGVFVSNGTHW
FVTQRNFYEPQIITTDNTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICAS
3:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDSK
(NTD)

176

78.37

0.3765

1:SAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK
AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNT
FVS(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTL(NTD)
3:KSFTVEKGIYQTSNFRVQPTESIVRFPNITNL
CPFGEVFNATRFASV(NTD,RBD)
177

78.92

0.3831

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTL(NTD)
3:KSFTVEKGIYQTSNFRVQPTESIVRFPNITNL
CPFGEVFNATRFASV(NTD,RBD)

178

79.44

0.3711

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTL(NTD)
3:KSFTVEKGIYQTSNFRVQPTESIVRFPNITNL
CPFGEVFNATRFASVY(NTD,RBD)

179

79.9

0.3709

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTL(NTD)
3:KSFTVEKGIYQTSNFRVQPTESIVRFPNITNL
CPFGEVFNATRFASVYA(NTD,RBD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

180

80.36

0.3669

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTL(NTD)
3:KSFTVEKGIYQTSNFRVQPTESIVRFPNITNL
CPFGEVFNATRFASVYA(NTD,RBD)

181

80.76

0.3571

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTL(NTD)
3:KSFTVEKGIYQTSNFRVQPTESIVRFPNITNL
CPFGEVFNATRFASVYAW(NTD,RBD)

182

81.13

0.3462

1:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTL(NTD)
3:KSFTVEKGIYQTSNFRVQPTESIVRFPNITNL
CPFGEVFNATRFASVYAW(NTD,RBD)

183

81.4

0.3463

1:SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAIC
HDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVS(CD)
2:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTL(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

3:KSFTVEKGIYQTSNFRVQPTESIVRFPNITNL
CPFGEVFNATRFASVYAW(NTD,RBD)
184

81.87

0.4447

1:LPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFN
DGVYFASTEKSNIIRGWIFGTTLDS(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNC(CD)
3:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICAS

185

82.34

0.4417

1:FLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPF
NDGVYFASTEKSNIIRGWIFGTTLDS(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNC(CD)
3:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICAS

186

82.81

0.4483

1:FLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPF
NDGVYFASTEKSNIIRGWIFGTTLDS(NTD)
2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNC(CD)
3:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICASY

187

83.34

0.4302

1:QDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPV
LPFNDGVYFASTEKSNIIRGWIFGTTLDS(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNC(CD)
3:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICA
188

83.88

0.4373

1:APHGVVFLHVTYVPAQEKNFTTAPAICHDGKA
HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICAS
3:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

189

84.43

0.4332

1:SAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK
AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNT
FVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICAS
3:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

190

84.97

0.4391

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICAS
3:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLD(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

191

85.48

0.4288

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICAS
3:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

192

85.94

0.4247

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICAS
3:TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDS
(NTD)

193

86.4

0.4573

1:QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG
KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDN
TFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICASYQTQ
3:DLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVL
PFNDGVYFASTEKSNIIRGWIFGTTLDS(NTD)

194

86.85

0.4532

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVSGNC(CD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICASYQTQ
3:DLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVL
PFNDGVYFASTEKSNIIRGWIFGTTLDS(NTD)
195

87.27

0.4748

1:PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHD
GKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTD
NTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICASYQTQ
3:DLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVL
PFNDGVYFASTEKSNIIRGWIFGTTLDSK(NTD)

196

87.64

0.4642

1:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICASYQTQ
3:DLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVL
PFNDGVYFASTEKSNIIRGWIFGTTLDSK(NTD)

197

87.92

0.4582

1:FPQSAPHGVVFLHVTYVPAQEKNFTTAPAICH
DGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITT
DNTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICASYQTQ
3:DLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVL
PFNDGVYFASTEKSNIIRGWIFGTTLDSKT
(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

198

88.19

0.4577

1:SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAIC
HDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIIT
TDNTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICASYQTQ
3:DLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVL
PFNDGVYFASTEKSNIIRGWIFGTTLDSKT
(NTD)

199

88.49

0.4588

1:LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPA
ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQI
ITTDNTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICASYQTQ
3:DLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVL
PFNDGVYFASTEKSNIIRGWIFGTTLDSK(NTD)

200

88.86

0.4584

1:HLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAP
AICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQ
IITTDNTFVSGNC(CD)
2:TEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC
LIGAEHVNNSYECDIPIGAGICASYQTQ
3:DLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVL
PFNDGVYFASTEKSNIIRGWIFGTTLDSK(NTD)

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Figure 1

Figure 1.- Immunogenic abilities of COVI19-NTD peptide in vaccine platforms. Mice (C57BL/6,
n = 5) hind footpads are inoculated with the DC vaccines (106 cells/mice) loaded with the
different peptides (COVID-19-NTD or peptide control) or remained as empty DC in
formulations with the adjuvant DIO-1 (40 ng/mL). 48 hours later, footpad swelling was
measured with a caliper (dark blue bars) and expressed as the differences in mm between left
and right hind footpads. Results are the mean ¬± SD of three different experiments (P < 0.05).
Popliteal lymph nodes are next isolated from mice legs and after homogenization, immune cell
populations are analyzed by flow cytometry. Percentages of CD4+ (red bars), CD8+ T cells
(green bars), CD19+ (B cells, purple bars) and MHC-II+ positive cells, mainly DC or macrophages
(light blue bars) are shown. Results are expressed as the percentages of positive cells ¬± SD of
three different experiments (P < 0.05).

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.30.403824; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Figure 2

Figure 2.- Cytokine levels of mice inoculated with DC vaccine platforms. Cytokine levels
detected in sera of mice as in Figure 1 and measured with a multiparametric Luminex kit from
Merck. Results are expressed as pg/mL of each cytokine ¬± SD of triplicate samples (P ‚â§ 0.5).

